Serum insulin-like growth factor-1 (IGF-1) levels have been correlated with an increased risk of developing prostate cancer. 1 The progression from androgendependent to androgen-independent prostate cancer is thought to be due to survival factors inducing apoptotic resistance in these cells. IGF-1 may represent a novel survival factor in prostate cancer. Over-expression of focal adhesion kinase (FAK) and anti-apoptotic proteins correlates with an increased metastatic phenotype. 2 The aim of this study was to determine if IGF-1 alters prostate cancer cell resistance to chemical and radiation induced apoptosis, and to examine the intracellular signalling mechanisms involved.
Method
LNCaP (androgen-dependent) and PC-3 (androgenindependent) prostate cancer cells were pre-treated (24 h) with and without IGF-1 (0 ± 100 ng/ml). Cells were then further incubated with and without apoptotic inducing agents (radiation, etoposide and cyclohexamide). Percent apoptosis was assessed by propidium iodide DNA staining, and con®rmed with annexin V staining of phosphatidylserine. using¯ow cytometry. Protein was extracted after IGF-1 (0 ± 50 ng/ml) treatment (24-h) and Western blotting carried out to assess Bcl-X L , Mcl-1, caspase 3, c-IAP-1/2 and survivin expression. PC-3 cells were incubated with IGF-1 (50 ng/ml) over 30 minutes. Immunoprecipitation of FAK was performed and FAK phosphorylation was assessed by Western blotting.
Results
Radiation (5 Gy), etoposide (60 mM) and cycloheximide (1mg/ml) induced signi®cant apoptosis in both PC-3 and LNCaP cells. Pre-incubation of these cells with IGF-1 in increasing doses (0 ± 100 ng/ml) conferred a resistance to apoptosis in both cell lines (Table 1) .
IGF-1 (0 ± 50 ng/ml) induced an increase in expression of both Bcl-X L and Mcl-1 anti-apoptotic proteins. There was no change in the inhibitors of apoptosis proteins c-IAP-1/2 or survivin. IGF-1 (50 ng/ml) also increased FAK phosphorylation in PC-3 cells at 10 minutes.
Conclusion
We have demonstrated that IGF-1 is a novel survival factor in prostate cancer. IGF-1 induces a resistance to apoptosis in two human prostate cancer cell lines and this appears to be mediated by the expression of the antiapoptotic proteins Bcl-X L and Mcl-1. The effects of IGF-1 are also associated with increased phosphorylation of FAK.
Altered apoptotic signalling may represent a novel mechanism by which IGF-1 stimulates tumour progression in prostate cancer. Bone, the principal site for metastases of prostate cancer, is rich in IGF-1 and these high levels may aid metastatic prostate cells to survive and proliferate. Manipulating IGF-1 signalling may be a therapeutic option in the treatment of androgen-independent prostate cancer. 
